绿叶制药正式开启ERZOFRI®在美商业化 首批出口美国药品成功发货

Group 1 - The core point of the article is that Green Leaf Pharmaceutical has officially commenced the commercialization of its schizophrenia drug ERZOFRI® in the U.S. market [1] - The first batch of ERZOFRI®, valued at several tens of millions of U.S. dollars, has been shipped from the Green Leaf International Pharmaceutical Technology Industrial Park [1] - This marks a significant milestone for the company as it expands its presence in the U.S. pharmaceutical market [1]